Oncogenic Kit Triggers Shp2/Erk1/2 Pathway to Down-Regulate the Pro-Apoptotic Protein Bim and to Promote Apoptosis Resistance in Leukemic Cells

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Selimoglu Buet, Dorothée ^a   Gallais, Isabelle ^a   Denis, Nicole ^a   Guillouf, Christel ^a   Moreau Gachelin, Françoise ^a  

^a INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BH3 PROTEIN; BIM PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MUTANT PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEASOME; PROTEIN TYROSINE PHOSPHATASE SHP 2; STEM CELL FACTOR RECEPTOR; UO 126;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INACTIVATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MOUSE; MURINE LEUKEMIA; NONHUMAN; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; DOWN-REGULATION; HUMANS; LEUKEMIA; MAP KINASE SIGNALING SYSTEM; MEMBRANE PROTEINS; MICE; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-KIT;

MURINAE;

EID: 84868672796     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049052     Document Type: Article

References (28)

1. Moreau-Gachelin F, Wendling F, Molina T, Denis N, Titeux M, et al. (1996) Spi-1/PU.1 transgenic mice develop multistep erythroleukemias. Mol Cell Biol 16: 2453-2463.
2. Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, et al. (2002) The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 99: 1741-1744.
3. Akin C, Brockow K, D'Ambrosio C, Kirshenbaum AS, Ma Y, et al. (2003) Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 31: 686-692.
4. Buet D, Gallais I, Lauret E, Denis N, Lombard B, et al. (2012) Cotargeting signaling pathways driving survival and cell cycle circumvents resistance to Kit inhibitors in leukemia. Blood 119: 4228-4241.
5. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, et al. (2008) Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7: 1851-1863.
6. Schimmer AD, O'Brien S, Kantarjian H, Brandwein J, Cheson BD, et al. (2008) A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res 14: 8295-8301.
7. Youle RJ, Strasser A, (2008) The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9: 47-59.
8. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, et al. (2010) The landscape of somatic copy-number alteration across human cancers. Nature 463: 899-905.
9. Reed JC, (2008) Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood 111: 3322-3330.
10. Meijerink JP, Mensink EJ, Wang K, Sedlak TW, Sloetjes AW, et al. (1998) Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. Blood 91: 2991-2997.
11. Tagawa H, Karnan S, Suzuki R, Matsuo K, Zhang X, et al. (2005) Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. Oncogene 24: 1348-1358.
12. Puthalakath H, Strasser A, (2002) Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ 9: 505-512.
13. Balmanno K, Cook SJ, (2009) Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ 16: 368-377.
14. Sirven A, Ravet E, Charneau P, Zennou V, Coulombel L, et al. (2001) Enhanced transgene expression in cord blood CD34(+)-derived hematopoietic cells, including developing T cells and NOD/SCID mouse repopulating cells, following transduction with modified trip lentiviral vectors. Mol Ther 3: 438-448.
15. Kosmider O, Denis N, Lacout C, Vainchenker W, Dubreuil P, et al. (2005) Kit-activating mutations cooperate with Spi-1/PU.1 overexpression to promote tumorigenic progression during erythroleukemia in mice. Cancer Cell 8: 467-478.
16. O'Connor L, Strasser A, O'Reilly LA, Hausmann G, Adams JM, et al. (1998) Bim: a novel member of the Bcl-2 family that promotes apoptosis. Embo J 17: 384-395.
17. Luciano F, Jacquel A, Colosetti P, Herrant M, Cagnol S, et al. (2003) Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene 22: 6785-6793.
18. Ewings KE, Hadfield-Moorhouse K, Wiggins CM, Wickenden JA, Balmanno K, et al. (2007) ERK1/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL. Embo J 26: 2856-2867.
19. Bennett AM, Hausdorff SF, O'Reilly AM, Freeman RM, Neel BG, (1996) Multiple requirements for SHPTP2 in epidermal growth factor-mediated cell cycle progression. Mol Cell Biol 16: 1189-1202.
20. Dijkers PF, Medema RH, Lammers JW, Koenderman L, Coffer PJ, (2000) Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol 10: 1201-1204.
21. Barnache S, Mayeux P, Payrastre B, Moreau-Gachelin F, (2001) Alterations of the phosphoinositide 3-kinase and mitogen-activated protein kinase signaling pathways in the erythropoietin-independent Spi- 1/PU.1 transgenic proerythroblasts. Blood 98: 2372-2381.
22. Ley R, Balmanno K, Hadfield K, Weston C, Cook SJ, (2003) Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem 278: 18811-18816.
23. Kuribara R, Honda H, Matsui H, Shinjyo T, Inukai T, et al. (2004) Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors. Mol Cell Biol 24: 6172-6183.
24. Aichberger KJ, Gleixner KV, Mirkina I, Cerny-Reiterer S, Peter B, et al. (2009) Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs. Blood 114: 5342-5351.
25. Will B, Siddiqi T, Jorda MA, Shimamura T, Luptakova K, et al. (2010) Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells. Blood 115: 2901-2909.
26. Hsu SY, Lin P, Hsueh AJ, (1998) BOD (Bcl-2-related ovarian death gene) is an ovarian BH3 domain-containing proapoptotic Bcl-2 protein capable of dimerization with diverse antiapoptotic Bcl-2 members. Mol Endocrinol 12: 1432-1440.
27. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, et al. (2006) The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10: 389-399.
28. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, et al. (2006) Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10: 375-388.